COMP <GO>
KURA vs AKTS // 10Y YIELD & FRED MACRO BETA
Kura Oncology Inc. (NASDAQ) VS. Aktis Oncology Inc. (NASDAQ) • 15-METRIC TALLY: KURA 2
— AKTS 0
■ METRIC PARITY
LAST: $10.56 (-1.49%) • MKT CAP: $939.4M
macro-sensitivity
—
LAST: $16.85 (+0.18%) • MKT CAP: $937.2M
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KURA VS. AKTS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KURA | AKTS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.53% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 25.20% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.1 | 44.3 | +8.80 | KURA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $939.4M | $937.2M | $2.2M | KURA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KURA REV | AKTS REV | KURA GROSS % | AKTS GROSS % | KURA FCF | AKTS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $67.5M | $0 | — | — | -$70.7M | — |
| FY 2024 | $53.9M | — | — | — | $133.8M | — |
| FY 2023 | $0 | — | — | — | -$124.8M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KURA // BETA —
AKTS // BETA —